Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemECD532hydrochlorideCat.No.:HY-112273A分?式:C??H??ClF?N?O分?量:558.99作?靶點(diǎn):AuroraKinase作?通路:CellCycle/DNADamage;Epigenetics儲(chǔ)存?式:4°C,sealedstorage,awayfrommoisture*Insolvent:-80°C,6months;-20°C,1month(sealed

storage,awayfrommoisture)溶解性數(shù)據(jù)體外實(shí)驗(yàn)DMSO:100mg/mL(178.89mM;Needultrasonic)MassSolvent1mg5mg10mgConcentration制備儲(chǔ)備液1mM1.7889mL8.9447mL17.8894mL5mM0.3578mL1.7889mL3.5779mL10mM0.1789mL0.8945mL1.7889mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；?旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。儲(chǔ)備液的保存?式和期限：-80°C,6months;-20°C,1month(sealedstorage,awayfrommoisture)。-80°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)?內(nèi)使?，-20°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)?內(nèi)使?。體內(nèi)實(shí)驗(yàn)請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥?式選擇適當(dāng)?shù)娜芙?案。以下溶解?案都請(qǐng)先按照InVitro?式配制澄的儲(chǔ)備液，再依次添加助溶劑：(為保證實(shí)驗(yàn)結(jié)果的可靠性，澄的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的?作液，建議您現(xiàn)?現(xiàn)配，當(dāng)天使?；以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的?式助溶)1.請(qǐng)依序添加每種溶劑：10%DMSO>>40%PEG300>>5%Tween-80>>45%salineSolubility:2.5mg/mL(4.47mM);Suspendedsolution;NeedultrasonicBIOLOGICALACTIVITY1/2MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemE?物活性CD532hydrochloride?種有效的AuroraA激酶抑制劑，IC50值為45nM。CD532hydrochloride具有阻斷AuroraA激酶活性和驅(qū)動(dòng)MYCN降解的雙重作?。CD532hydrochloride還可以直接與AURKA相互作?并誘導(dǎo)整體構(gòu)象轉(zhuǎn)變。CD532hydrochloride可?于癌癥的研究。REFERENCES[1].GustafsonWC,et,al.DruggingMYCNthroughanallosterictransitioninAurorakinaseA.CancerCell.2014Sep8;26(3):414-427.[2].LeeJK,et,al.N-MycDrivesNeuroendocrineProstateCancerInitiatedfromHumanProstateEpithelialCells.CancerCell.2016Apr11;29(4):536-547.McePdfHeightCaution:Producthasnotbeenfullyvalidatedformedicalapplications.Forresearchuseonly.Tel:400-820-3792;021-589